July 23 (Reuters) - AMAG Pharmaceuticals Inc AMAG.O :
* AMAG PHARMACEUTICALS AND NORGINE B.V. ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE CIRAPARANTAG IN EUROPE, AUSTRALIA AND NEW ZEALAND
* AMAG PHARMACEUTICALS INC - AGREEMENT PROVIDES AMAG WITH $30 MILLION UPFRONT PAYMENT
* AMAG PHARMACEUTICALS INC - AGREEMENT PROVIDES AMAG WITH $30 MILLION UPFRONT PAYMENT
* AMAG PHARMA - AGREEMENT PROVIDES CO WITH ELIGIBILITY TO RECEIVE UP TO $260 MILLION IN DEVELOPMENT AND COMMERCIAL MILESTONES IN ADDITION TO SALES ROYALTIES
* AMAG PHARMACEUTICALS INC - NORGINE HAS COMMITTED TO CONTRIBUTE ONE-THIRD OF COSTS OF PHASE 3 CLINICAL PROGRAM